Nyxoah (NYXH) Set to Release Quarterly Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nyxoah to post earnings of ($0.3510) per share and revenue of $11.00 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Thursday, August 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. The business had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $8.64 million. On average, analysts expect Nyxoah to post ($1.44) EPS for the current fiscal year and ($0.79) EPS for the next fiscal year.

Nyxoah Stock Down 1.2%

Nyxoah stock opened at $0.90 on Thursday. The stock has a 50 day moving average of $1.38 and a two-hundred day moving average of $2.56. Nyxoah has a twelve month low of $0.80 and a twelve month high of $5.92. The stock has a market capitalization of $34.88 million, a price-to-earnings ratio of -0.36 and a beta of 1.65. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44.

Analysts Set New Price Targets

Several analysts have recently weighed in on NYXH shares. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 target price (down from $7.00) on shares of Nyxoah in a report on Thursday, August 6th. Raymond James Financial set a $3.00 price target on shares of Nyxoah in a report on Tuesday. Wall Street Zen downgraded shares of Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a research report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nyxoah in a report on Wednesday, August 19th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Nyxoah has a consensus rating of “Hold” and an average target price of $3.55.

Nyxoah Company Profile

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.